Salix Pharma will buy Santarus for $2.12 billion

Salix Pharmaceuticals will buy Santarus for about $2.12 billion to add to its roster of drugs.

Salix will pay $32 per share for Santarus' stock, the drugmakers said Thursday. They say the deal values Santarus at $2.6 billion.

Salix Pharmaceuticals Ltd., based in Raleigh, N.C., is paying a 38 percent premium to Santarus Inc.'s closing price of $23.22 Thursday.

The boards of both companies have approved the deal and say they expect the sale to close during the first quarter.

Salix sells Xifaxan, a treatment for traveler's diarrhea and associated with , the ulcerative colitis drug Apriso, and constipation drug Relistor.

San Diego-based Santarus, whose stock price has more than doubled this year, sells Glumetza for diabetes, Zegerid for , and Uceris for ulcerative colitis.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Actavis buying Warner Chilcott in $8.5B deal

May 20, 2013

Actavis is buying Warner Chilcott in an all-stock deal valued at about $8.5 billion that would create the third-biggest specialty pharmaceutical company in the U.S. market.

Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Recommended for you

US must respond to global health outbreaks, say bioethicists

Mar 05, 2015

Last summer, West Africa fell into the grip of a deadly outbreak of Ebola that has thus far taken the lives of more than 9,500 people. The fear swept up by the epidemic quickly jumped across the Atlantic and landed in the ...

Uganda on defensive over medical 'brain drain' uproar

Mar 03, 2015

Uganda's government on Tuesday hit back at mounting criticism of plans to 'export' over 200 health workers to the Caribbean, insisting it was only seeking to regulate an existing labour market and prevent abuses.

Seth Mnookin on vaccination and public health

Mar 02, 2015

Seth Mnookin, an assistant professor of science writing and associate director of MIT's Graduate Program in Science Writing, is the author of "The Panic Virus: The True Story Behind the Vaccine-Autism Controversy" ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.